"目錄號(hào): HY-13676
Megestrol醋酸鹽能抑制HegG2蔑穴，IC50為260 μM。
Progesterone ReceptorAutophagy
相關(guān)產(chǎn)品
Cycloheximide-TAK-242-LY294002-3-Methyladenine-(+)-JQ-1-SB 203580-SP600125-U0126-Enzalutamide-Actinomycin D-Olaparib-Doxorubicin hydrochloride-Dorsomorphin dihydrochloride-Mitomycin C-Bortezomib-
生物活性
Description
Megestrol Acetate is a synthetic progesteronal agent with an IC50 of 260 μM for the inhibition of HegG2.Target: Progesterone ReceptorMegestrol acetate, also known as 17α-acetoxy-6-dehydro-6-methylprogesterone, and sometimes abbreviated as MGA or MA, is a steroidal progestin and progesterone derivative (specifically, a 17-hydroxylated progesterone) with predominantly progestational and antigonadotropic effects. Megestrol acetate is a good candidate for muscle wasting treatment and future studies addressed at the interaction between the drug and protein turnover in human skeletal muscle should be performed.
Clinical Trial
Xiaojun Chen-Fudan University-Shanghai 6th People's Hospital-Zhejiang Cancer Hospital-Shanghai Changning Maternity & Infant Health Hospital
Endometrial Atypical Hyperplasia-Endometrial Adenocarcinoma
October 2013
Phase 2
Endo Pharmaceuticals-Quintiles, Inc.
HIV Infections-Cachexia-Anorexia-AIDS Wasting Syndrome-HIV Wasting Syndrome
December 2004
Phase 2
Southwest Oncology Group-National Cancer Institute (NCI)
Breast Cancer-Hot Flashes
April 1998
Phase 3
The First Affiliated Hospital of Henan University of Science and Technology
Stage III Esophageal Squamous Cell Carcinoma-Stage II Esophageal Squamous Cell Carcinoma
October 2014
Phase 3
New York University School of Medicine
Atypical Endometrial Hyperplasia-Endometrial Carcinoma
June 2007
Phase 2
Endo Pharmaceuticals-SFBC Anapharm
Pharmacokinetics-Bioavailability-Absorption
June 2006
Phase 1
University of South Florida-National Cancer Institute (NCI)
Brain Tumor-Central Nervous System Tumors-Cachexia-Leukemia-Lymphoma-Myelodysplastic Syndromes-Myelodysplastic/Myeloproliferative Diseases-Unspecified Childhood Solid Tumor, Protocol Specific
June 2003
Phase 2
Par Pharmaceutical, Inc.-PRA Health Sciences
Anorexia-Cachexia-Weight Loss
June 2006
Phase 3
Par Pharmaceutical, Inc.-PRA Health Sciences
Anorexia-Cachexia-Weight Loss
June 2006
Phase 3
Rottapharm Spain
Dementia
June 2007
Phase 2-Phase 3
Washington University School of Medicine
Anorexia
September 2013
Phase 2
Rottapharm Spain
Chronic Obstructive Pulmonary Disease
October 2006
Phase 2
University of Texas Southwestern Medical Center-The Rogosin Institute
Cognitive Impairment
July 2015
Early Phase 1
Pfizer
Metastatic Breast Cancer
November 2001
Phase 3
Wake Forest University Health Sciences-National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific-Weight Changes
March 2004
Phase 3
University of Arkansas
Adrenal Insufficiency
April 2004
TTY Biopharm-Chang Gung Memorial Hospital
Head and Neck Cancer
May 2015
Phase 2
Gamma Project - ACTU-NIH AIDS Clinical Trials Information Service
HIV Infections
Mayo Clinic-National Cancer Institute (NCI)
Anorexia-Weight Changes
March 2011
Phase 2
University of Southern California-National Cancer Institute (NCI)
Atypical Endometrial Hyperplasia-Endometrial Adenocarcinoma-Recurrent Endometrial Carcinoma-Stage IA Endometrial Carcinoma-Stage IB Endometrial Carcinoma-Stage II Endometrial Carcinoma-Stage IIIA Endometrial Carcinoma-Stage IIIB Endometrial Carcinoma-Stage IIIC Endometrial Carcinoma-Stage IVA Endometrial Carcinoma-Stage IVB Endometrial Carcinoma
March 2014
Phase 2
Bristol-Myers Squibb
Anorexia-Cachexia-HIV Infections
Phase 3
Bristol-Myers Squibb
Anorexia-Cachexia-HIV Infections
Phase 2
Alliance for Clinical Trials in Oncology-National Cancer Institute (NCI)-NCIC Clinical Trials Group
Anorexia-Cachexia
March 2000
Phase 3
National Medical Research Council (NMRC), Singapore-National Cancer Institute (NCI)
Liver Cancer
May 2002
Phase 3
Par Pharmaceutical, Inc.-Covance-SFBC Anapharm
Healthy
May 2006
Phase 1
St. Vincent Medical Center - Los Angeles-National Cancer Institute (NCI)
Breast Cancer-Endometrial Cancer-Malignant Mesothelioma
December 1987
Phase 1-Phase 2
Northwestern University-National Cancer Institute (NCI)
Cachexia-Fatigue-Unspecified Adult Solid Tumor, Protocol Specific
January 2000
Phase 2
Wake Forest University Health Sciences-National Cancer Institute (NCI)
Anorexia-Cachexia-Lung Cancer
September 2000
Phase 3
Wake Forest University Health Sciences-National Cancer Institute (NCI)
Anorexia-Cachexia-Head and Neck Cancer-Quality of Life
October 2000
Phase 3
National Institute of Allergy and Infectious Diseases (NIAID)-Roxane Laboratories-Bristol-Myers Squibb
Cachexia-HIV Infections-HIV Wasting Syndrome
Phase 1
Instituto Nacional de Cancer, Brazil-Cancer Research UK Cambridge Institute
Breast Neoplasm
March 2017
Phase 2
Bristol-Myers Squibb
Anorexia-Cachexia-HIV Infections
Phase 4
Ipsen
Endometrial Cancer
August 2009
Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections-HIV Wasting Syndrome
Phase 2
Centre Oscar Lambret
Cancer
September 2006
Phase 2
Gynecologic Oncology Group-National Cancer Institute (NCI)
High Grade Squamous Intraepithelial Neoplasia-Stage 0 Uterine Corpus Cancer
July 2007
Phase 2
National Cancer Institute (NCI)
Endometrial Carcinoma-Recurrent Uterine Corpus Carcinoma-Stage IIIA Uterine Corpus Cancer-Stage IIIB Uterine Corpus Cancer-Stage IIIC1 Uterine Corpus Cancer-Stage IIIC2 Uterine Corpus Cancer-Stage IVA Uterine Corpus Cancer-Stage IVB Uterine Corpus Cancer
September 2008
Phase 2
National Center for Research Resources (NCRR)-Northwestern University-Office of Rare Diseases (ORD)
Acquired Immunodeficiency Syndrome-HIV Wasting Syndrome-HIV Infections
June 1995
Ann Davis, PhD, MPH, ABPP-Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)-University of Kansas Medical Center
Chronic Oral Food Refusal
August 2010
Phase 2
Xinqiao Hospital of Chongqing-Chengdu University of Traditional Chinese Medicine
Anorexia-Cancer Cachexia
December 2015
Phase 2-Phase 3
Gynecologic Oncology Group-National Cancer Institute (NCI)
Endometrial Cancer
May 2001
Phase 3
Merck Sharp & Dohme Corp.
Endometrial Cancer
August 2008
Phase 2
Emory University-Novartis
Estrogen Receptor-positive Breast Cancer-HER2-negative Breast Cancer-Progesterone Receptor-positive Breast Cancer-Recurrent Breast Cancer-Stage IIIA Breast Cancer-Stage IIIB Breast Cancer-Stage IIIC Breast Cancer-Stage IV Breast Cancer
November 2014
Phase 2
Yale University
Breast Cancer
February 1994
Phase 2
Merck Sharp & Dohme Corp.
Dysmenorrhea
January 2013
Phase 2
Merck Sharp & Dohme Corp.-CRS Mannheim GmbH
Healthy
May 2007
Phase 1
Merck Sharp
